The results showed that high expression of TMPRSS2 in breast cancer has a poor prognosis in enriched CD4+ T cells (HR = 1.78 p < 0.01) and enriched CD8+ T cells (HR = 3.52 p < 0.001) (Figures 5A, C). This evidence concerns the gene CD4 and breast carcinoma.